Buradasınız

Anasayfa » Content

Adrenokortikal Karsinomlu Olgularımızın Retrospektif Değerlendirilmesi

Retrospective Evoluation of Adrenocortical Carcinoma Patients

Journal Name:

  • Uludağ Üniversitesi Tıp Fakültesi Dergisi

Publication Year:

  • 2007

Key Words:

Keywords (Original Language):

Author NameUniversity of Author
Abstract (2. Language): 
Adrenocortical carcinoma (ACC) is a rare and aggressive tumor with a poor prognosis. In this study, we retrospectively evaluated clinical features and treatment results of our ACC patients. A total of eight patients with ACC were treated in our department. All patients had metastatic disease. Patients received etoposide, doxorubicin and cisplatin (EAP) or etoposide and cisplatin regimen (EP). Stabile disease was observed in four patients and progressive disease in four. At a mean follow up 7.7 months (range, 3-15 months) 5 patients died from progressive disease. Our findings reflect the aggressive nature of ACC.
Bookmark/Search this post with
Abstract (Original Language): 
Adrenokortikal karsinom (AKK) nadir ve agresif bir tümor olup prognozu kötüdür. Bu çalışmada, AKK hastalarımızın klinik özellikleri ve tedavi sonuçları retrospektif olarak değerlendirildi. Departmanımızda, toplam sekiz AKK’lu hasta tedavi edildi. Hastaların tamamında metastaz mevcuttu. Hastalara etoposid, doksorubisin ve sisplatin (EAP) veya etoposid ve sisplatin (EP) rejimi uygulandı. Dört hastada stabil hastalık, diğer dört hastada ise progresyon olduğu gözlendi. Ortalama 7.7 aylık (3-15 ay) takipte 5 hasta progresif hastalık nedeniyle öldü. Bulgularımız AKK’un agresif doğasını yansıtmaktadır.
FULL TEXT (PDF): 
PDF icon arastirmax-adrenokortikal-karsinomlu-olgularimizin-retrospektif-degerlendirilmesi.pdf
  • 1
1-3
  • Turkish

REFERENCES

References: 

1. Roman S. Adrenocortical carcinoma. Curr Opin Oncol
2006;18:36-42.
2. Ahlman H, Khorram-Manesh A, Jansson S, et al. Cytotoxic
treatment of adrenocortical carcinoma. World J Surg
2001;25:927-33.
3. Koschker AC, Fassnacht M, Hahner S, Weismann D, Allolio
B. Adrenocortical carcinoma -- improving patient care by
establishing new structures. Exp Clin Endocrinol Diabetes
2006;114:45-51
4. Meyer A, Niemann U, Behrend M. Experience with the
surgical treatment of adrenal cortical carcinoma. Eur J Surg
Oncol 2004;30:444-9.
5. Berruti A, Terzolo M, Pia A, Angeli A, Dogliotti L. Mitotane
associated with etoposide, doxorubicin, and cisplatin in the
treatment of advanced adrenocortical carcinoma. Italian Group
for the Study of Adrenal Cancer. Cancer 1998;83(10):2194-
200
6. Williamson SK, Lew D, Miller GJ, Balcerzak SP, Baker LH,
Crawford ED. Phase II evaluation of cisplatin and etoposide
followed by mitotane at disease progression in patients with
locally advanced or metastatic adrenocortical carcinoma: a
Southwest Oncology Group Study. Cancer 2000;88(5):1159-
65.
7. Bonacci R, Gigliotti A, Baudin E, et al. Cytotoxic therapy
with etoposide and cisplatin in advanced adrenocortical
carcinoma. Reseau Comete INSERM. Br J Cancer
1998;78:546-9.
8. Vassilopoulu Sellin R, Saaman NA. Mitotan administration:
an unusual cause of hypercholesterolemia. Horm Metab Res
1991;23:619-20.

Thank you for copying data from http://www.arastirmax.com